Could a direct brain injection of a Clot-Buster boost stroke recovery?
NCT ID NCT05172934
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This trial tests whether giving a clot-busting drug called tenecteplase directly into the brain artery, right after a standard procedure to remove a clot, can help people who have had a severe ischemic stroke. The study includes adults aged 18-85 with a blocked artery in the front part of the brain, treated within 24 hours of symptoms. Participants receive the drug after successful clot removal and are followed for three months to check for bleeding and measure their recovery and disability levels.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- intra-arterial tenecteplase
- What this could lead to
- If successful, this approach could improve recovery and reduce disability after a major stroke by clearing residual clots that standard treatment leaves behind.
- What could go wrong
- This is a small pilot study, so results may not apply broadly. The main risk is bleeding in the brain, which the trial closely monitors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
20 people
The number who actually took part.
- Started
-
Apr 2022
- Finished
-
Nov 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1\. Age 18-85 * 2\. Anterior circulation ischemic stroke symptoms with confirmed occlusion (ICA, M1, or M2) on angiogram and mechanical thrombectomy initiated within 24 hours since last known well * 3\. a. Patients treated less than 6 hours since last known well with ASPECTS \>6. b. Patients treated beyond 6 hours since last known well, CT or MRI perfusion scan showing favorable mismatch profile (Target mismatch profile on CT perfusion or MRI (ischemic core volume is \<70ml, mismatch ratio is \>1.8 and mismatch volume is \>15ml) * 4\. Post-mechanical thrombectomy with ≤5 device passes and mTICI grade 2b or 2c with persistent occlusion(s) in terminal branches not amenable to MT. * 5\. Signed informed consent Exclusion Criteria: * 1\. Premorbid modified Rankin scale (mRS) score of 4 or greater * 2\. Presence of any hemorrhage and/or ASPECT score ≤6 on baseline head CT * 3\. Platelet count \<100,000 * 4\. Known bleeding diathesis * 5\. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency * 6\. Active anticoagulation treatment with novel oral anticoagulant (NOACs) taken within the last 48 hours, or INR \>1.8 * 7\. Patients requiring active treatment with dual antiplatelet agents (e.g. proximal cervical carotid artery stenting) * 8\. Pregnant or lactating * 9\. Previous known allergy to TNK * 10\. Major surgery in past 30 days * 11\. Patient is on or requires dialysis * 12\. History of intracranial hemorrhage or serious head trauma at any time * 13\. Any condition in the opinion of the enrolling physician that would preclude the patient from participating * 14\. Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluation * 15\. Severe, uncontrolled hypertension (systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg) that is refractory to treatment * 16\. History of acute ischemic stroke in the last 60 days * 17\. Presumed septic embolus; suspicion of bacterial endocarditis * 18\. Suspicion of aortic dissection * 19\. Intracranial neoplasm * 20\. Any mass effect * 21\. Any terminal medical condition with life expectancy less than 6 months * 22\. Concurrent enrollment in another trial that could confound the results of this study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ProMedica Toledo Hospital
Toledo, Ohio, 43606, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a checklist and heart monitor stop repeat strokes?
- Heart hole or stroke trigger? global registry tracks who gets closure and what happens next
- Two ways to catch a hidden heart rhythm after stroke
- Blood test may reveal who recovers after a stroke
- Can a smart bracelet and app stop a second stroke?
- Pharmacist and coach team takes aim at blood pressure after stroke